Oncology

Breast Cancer CAF Metabolic Reprogramming Emerges as a Tumor Driver

A Frontiers in Immunology review examines how metabolic rewiring in cancer-associated fibroblasts fuels breast cancer growth, immune evasion,…

Extracellular Vesicles Drive Immune Escape in Osteosarcoma

A Frontiers in Immunology review maps how osteosarcoma extracellular vesicles reprogram immunity, with major gaps in human validation…

HER2-Driven Lung Adenocarcinoma Case Shows Hyperprogression After Immunotherapy

A metastatic HER2-mutant lung adenocarcinoma case links ivonescimab exposure to hyperprogression, then rapid response to trastuzumab rezetecan.

PARP1 and PD-L1 Dual Inhibitor SP-1 Shows TNBC Activity

SP-1 blocked PARP1 and PD-L1 in preclinical testing, restrained triple-negative breast cancer cells, and restored T-cell function.

TLS and tumor-draining lymph nodes during checkpoint blockade

A Frontiers review maps how tertiary lymphoid structures and tumor-draining nodes sustain clonal responses during checkpoint blockade.

Risvutatug rezetecan shows promise in relapsed osteosarcoma phase 3 trial

Phase III ARTEMIS-011 suggests anti-B7-H3 ADC risvutatug rezetecan may improve outcomes in relapsed or refractory metastatic osteosarcoma.

Deep learning improves lung nodule assessment in NIR-nCLE imaging

Deep neural networks classified NIR-nCLE lung nodule recordings with high sensitivity and AUROC, though external validation remains essential.

TMEM45A links triple-negative breast cancer to depression in preclinical study

Preclinical work links TMEM45A overexpression in triple-negative breast cancer to depression-like behavior through AKT/mTOR signaling in cells and…

Integrated live-cell imaging platform advances photodynamic therapy research

A new incubator-compatible platform links live-cell imaging and photodynamic therapy, enabling repeated observation of the same cells over…